3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Rhabdoid Tumor
1
Papillary renal cell carcinoma, sporadic
1
Oropharyngeal Neoplasms
1
Neoplasms, Squamous Cell
1
Neoplasms, Basal Cell
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mouth Neoplasms
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer
1
Liver Cirrhosis
1
Laryngeal Neoplasms
1
Kidney Neoplasms
1
Hypopharyngeal Neoplasms
1
Hereditary leiomyomatosis and renal cell cancer
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Choroid Plexus Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Hepatocellular
1
Carcinoma
1
Breast Neoplasms
1
Interventions
Gemcitabine
15
Cisplatin
13
durvalumab
12
pembrolizumab
10
Oxaliplatin
8
Magnetic Resonance Spectroscopy
8
Biopsy
7
Specimen Handling
6
Leucovorin
6
Fluorouracil
5
Paclitaxel
4
Folfox protocol
4
futibatinib
3
Taxes
3
Radiation
3
Nivolumab
3
Irinotecan
3
Immunoglobulin G
3
Disulfides
3
tislelizumab
2
pemigatinib
2
olaparib
2
lenvatinib
2
fludarabine
2
dehydroftorafur
2
Radiation Dose Hypofractionation
2
Platinum
2
Liver Transplantation
2
Fluorodeoxyglucose F18
2
Floxuridine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Cholangiocarcinoma
×
Erlotinib Hydrochloride
×
90 days
×
Clear all
No trials found.